Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).
According to a new study, patients with head and neck cancer who have more chromosome 9 genetic material in their cancer cells survive three times longer after accepting immunotherapy than patients who have less of it.
The energy centers of cells and mitochondria have their own genetic material and RNA molecules.
Mount Sinai researchers have solved a major mystery in cancer research: How cancer cells remain dormant for years after they leave a tumor and travel to other parts of the body, before awakening to create metastatic cancer.
In three studies from the Cancer Cell Map Initiative, researchers uncovered previously unknown interactions between proteins that drive cancer and combined this new data to generate a map of protein pathways informing cancer outcomes.
In a new study, researchers have introduced DSER, a technique for identifying molecular targets for enhanced therapy in prostate cancer.
Up to half of patients with head and neck squamous cell carcinoma will experience tumor recurrence or new tumors--tumors that often spread and are difficult to treat.
Chemotherapy is a drug treatment that uses powerful chemicals to kill fast-growing cancer cells in the body. It is a systemic treatment where drugs travel throughout the body and destroy cancer cells that have spread (metastasized) to parts of the body far away from the original (primary) tumour.
Scientists were able to considerably delay the growth and proliferation of tumors in mice and improve the effectiveness of immunotherapy.
Researchers at the Francis Crick Institute, the UCL Cancer Institute, and the Cancer Research UK Lung Cancer Centre of Excellence have identified genetic changes in tumours which could be used to predict if immunotherapy drugs would be effective in individual patients.
Researchers have found new clues about why certain individuals with head and neck cancer are able to respond to immunotherapy, while others fail to do so.
According to a study, researchers have successfully designed natural killer immune cells that destroy head and neck tumor cells in mice.
A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Solove Research Institute has identified a protein within certain immune cells that is required for optimal immune responses to cancer.